Margriet Piersma‐Wichers

Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. a retrospective study of 2300 consecutive patients with venous thromboembolism

Nic J.G.M. Veeger, Margriet Piersma‐Wichers, Jan G.P. Tijssen et al. · British Journal of Haematology · 2005 · 208 citations

Medicine, Pharmacology, Pharmacotherapy +17

Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial

Arina J. ten Cate‐Hoek, Elham E Amin, A.C. Bouman et al. · The Lancet Haematology · 2017 · 98 citations · Full text

Medicine, Surgery, Vascular Surgery +5

Risk of Bleeding and Thrombosis in Patients 70 Years or Older Using Vitamin K Antagonists

Hilde Kooistra, Agneta Calf, Margriet Piersma‐Wichers et al. · JAMA Internal Medicine · 2016 · 50 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype

Arian Plat, Alieke A C van Dijk, Margriet Piersma‐Wichers et al. · Thrombosis and Haemostasis · 2003 · 45 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation

Jennie Korenstra, Petra Wijtvliet, Nic J.G.M. Veeger et al. · EP Europace · 2016 · 40 citations · Full text

Medicine, Cardiology, Pharmacotherapy +12